B-ALL MRD testing has two parts based on COG consensus and is approved by COG. 1) a 5-antibody panel for blood sample from patients on day 8 of induction, and 2) a 12-antibody panel for bone marrow sample from patients on day 29 of induction. This 12-antibody panel is suitable for all MRD monitoring on bone marrow specimen from either pediatric or adult patients. The test uses a sequential gating strategy to isolate leukemic cells from normal mature and immature B-cells in the background. The test detects 1 B-ALL cell in 10,000 normal B-cells (0.01%). It provides a quantitative measurement of the MRD status and a trending graph in the report. Patients who achieve MRD-negative status have improved overall and progression-free survival. This test is not suitable for making primary diagnosis of B-ALL.
There must be a minimum of 5 million cells in the specimen submitted to perform the test (10 million cells preferred).
Information on collection, storage, and volume
Whole blood or bone marrow
10 mL whole blood; 2 mL bone marrow aspirate
Green-top (sodium heparin) tube (preferred) or lavender-top (EDTA)
Maintain specimen at room temperature.
Hemolysis; specimen clotted; specimen frozen; specimen in formalin or other fixative; blood more than 72 hours old; bone marrow aspirates more than five days old; bags or bottles of body fluid or bronchial washing; tissue in formalin or other fixative; contaminated transport medium
All specimens should be shipped to Labcorp Oncology on the day of excision. Delay in shipping may compromise cell viability and results.
Find more tests related to this one.